Replies to post #6783 on Cel Sci Corporation (CVM)

[maverick1856]

GK: If head-and-neck cancer is all we ever succeed with, we will be a multibillion-dollar company. If we succeed in this Phase 3 trial, one might expect that Multikine will become part of the new standard of care. Reimbursement and use should be no problem. If we capture 25% of the total annual patient population of 600,000 (600K), CEL-SCI will treat 150K patients at an assumed price of $100K each. Even with 25% of the annual diagnoses, Multikine can capture $15 billion ($15B) in market share without addressing any other disease or indication.

So they will be targeting $100k per patient treatment...with the current facility being able to handle ~3k patient treatment doses (~15 injections per patient and full capacity being 60k once expanded out) that would be around $300m in revenue the first year alone...

[Foxwoods Man]

2) CEL-SCI Corp. paid Streetwise Reports to conduct, produce and distribute the interview.

Paid advertisement...but still an ad with some decent info